ARONJ Conference Presentations

ARONJ Conference 12.09.2016 London, Dietmar W. Hutmacher

ARONJ Conference London, 12.09.2016

Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ)—Prevention of Bisphosphonate-Related Osteonecrosis of the Jaws Using a Novel Tissue Engineering Strategy

Consultant: Dietmar W. Hutmacher

ARONJ Conference 12.09.2016 London, Hadar ZIgdon Giladi

ARONJ Conference London, 12.09.2016

Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ)—The use of Endothelial Progenitor Cells (EPC) to treat BRONJ

Consultant: Hadar ZIgdon Giladi

ARONJ Conference 12.09.2016 London, Sven Otto

ARONJ Conference London, 12.09.2016

Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ)—Large animal model for Antiresorptive Drug-Related Osteonecrosis of the Jaw

Consultant: Sven Otto

ARONJ Conference 12.09.2016 London, Martin Stoddart

ARONJ Conference London, 12.09.2016

Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ)—Bisphosphonate Related Osteonecrosis of the Jaw.Role of soft tissue healing

Consultant: Martin Stoddart

ARONJ Conference 12.09.2016 London, Natasha Appelman-Dijkstra

ARONJ Conference London, 12.09.2016

Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ)—Bisphosphonates and Denosumab—Mechanism of action and their applicationsin Osteoporosis and Oncology

Consultant: Natasha Appelman-Dijkstra

ARONJ Conference 12.09.2016 London, Robert Marx

ARONJ Conference London, 12.09.2016

Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ)—Anti-resorptive Drug Osteonecrosis of the Jaws: The Continuing Epidemic

Consultant: Robert Marx